Just months after it made its RSNA debut, Garbsen, Germany-based industrial x-ray developer feinfocus Medizintechnik has decided to cease its healthcare device development efforts. The company attributed its decision in part to the difficulty U.S. firms,
Just months after it made its RSNA debut, Garbsen, Germany-based industrial x-ray developer feinfocus Medizintechnik has decided to cease its healthcare device development efforts. The company attributed its decision in part to the difficulty U.S. firms, such as Trex Medical, have encountered in obtaining clearance for digital mammography units from the Food and Drug Administration (SCAN 8/18/99).
The company had evaluated the medical market and concluded that its high-resolution x-ray technology could contribute to the industry. At the 1998 RSNA show, feinfocus displayed its work-in-progress DIMA (direct magnification) Plus M12 Mammography System, an upright full-field digital mammography unit with a 16 x 12-inch amorphous silicon detector. Feinfocus planned to begin its clinical investigations with the unit by installing a DIMA Plus M12 unit in 1999 (SCAN Special Report 1/99).
But since the November meeting, feinfocus shareholders have decided to sell the companys medical business and concentrate on its primary concern, the production and sale of microfocus x-ray systems for the inspection of electronic devices, semiconductors, aircraft, automobiles, and castings. With cost cuts in the German healthcare sector, and the obstacles that face vendors seeking FDA clearance, feinfocus believes that developing digital mammography systems would require more resources than the 70-employee firm has at its disposal, according to Friedhelm Maur, marketing and sales director. Feinfocus may continue to develop and sell its x-ray tube for medical applications, but will not produce and market a complete system.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.